NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

SI-BONE, Inc. (SIBN) Stock Analysis

SI-BONE, Inc. (SIBN) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

SIBN

$18.50

−$0.14 (−0.75%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SIBN with… →

SIBN Key Statistics

As of Sep 4, 2026
Trading
Open
$18.50
Previous Close
$18.64
Day's Range
18.20–18.75
52-Week Range
11.48–21.89
Volume
389.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$829.14M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.88
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.33
Financials (FY)
Revenue (FY)
$200.93M+20.19%
Net Income (FY)
−$18.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
−6.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
44.82M
1-Year Return
+13.15%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
557.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SIBN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.19%
2025+40.66%
2024−33.21%
2023+54.34%
2022−38.77%
2021−25.72%
2020+39.07%
2019+2.92%
2018 (partial year)+4.14%

As of September 4, 2026.

SIBN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$200.93M−$18.90M−9.4%
2024$167.18M−$30.91M−18.5%
2023$138.89M−$43.34M−31.2%
2022$106.41M−$61.26M−57.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$200.93M$159.88M−$22.33M−$18.90M−9.4%
2024$167.18M$132.12M−$35.25M−$30.91M−18.5%
2023$138.89M$109.42M−$46.93M−$43.34M−31.2%
2022$106.41M$90.70M−$59.61M−$61.26M−57.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SIBN Valuation vs Medical Devices Median

Median of 151 stocks
MetricSIBNMedical Devices medianvs median
P/S ratio3.882.9830% above
Profit margin−6.85%−1.69%5.2 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SI-BONE, Inc. (SIBN) at $829.14M. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 376 employees.

Over the past 52 weeks the price has ranged from $11.48 to $21.89. The most recent close on file for SIBN is $18.50, dated September 4, 2026. That is −$0.14 (−0.75%) against the previous close. The latest close sits 61.15% above that 52-week low.

Financial Health

In fiscal 2025, SI-BONE, Inc. reported revenue of $200.93M. That is +20.19% against the prior fiscal year, when revenue was $167.18M. The same year closed with a net loss of $18.90M. The reported profit margin is −6.85%. That is 5.2 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.33.

Across the 4 fiscal years on file, revenue moves from $106.41M in 2022 to $200.93M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.88 times revenue. On price-to-sales that is 30.43% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +13.15%. Measured over 5 years, that is −5.90% a year compounded. The reported beta is 0.71. Daily returns over the trailing 7 years annualize to a volatility of 54.76%.

Growth & Income

No dividend is on file for SIBN.

The strongest complete calendar year on file is 2023 at +54.34%; the weakest is 2022 at −38.77%. Of the 7 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −6.19% year to date.

Peer Comparison

SI-BONE, Inc. (SIBN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SI-BONE, Inc. SIBN $829.14M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. SI-BONE, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About SI-BONE, Inc.

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Visit website →